Torrent Pharmaceuticals · NSE: TORNTPHARM · BSE: 500420
Q3 FY19 results · Oct–Dec 2018
Torrent Pharmaceuticals reported revenue from operations of ₹2,051.00 crore and net profit of ₹246.00 crore for Q3 FY19 (Oct–Dec 2018), on a consolidated basis.
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,051.00 | — | — | 1,894.00 | +8.3% |
| Other income | 3.00 | — | — | 10.00 | −70.0% |
| Total income | 2,054.00 | — | — | 1,904.00 | +7.9% |
| Profit before tax | 275.00 | — | — | 205.00 | +34.1% |
| Net profit for the period | 246.00 | — | — | 179.00 | +37.4% |
| EPS, basic (₹) | 14.50 | — | — | 10.57 | +37.2% |
| Net margin (%) | 12.0 | — | 9.5 |
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,481.00 | — | — | 1,472.00 | +0.6% |
| Other income | 13.00 | — | — | 108.00 | −88.0% |
| Total income | 1,494.00 | — | — | 1,580.00 | −5.4% |
| Profit before tax | 192.00 | — | — | 300.00 | −36.0% |
| Net profit for the period | 182.00 | — | — | 277.00 | −34.3% |
| EPS, basic (₹) | 10.73 | — | — | 16.38 | −34.5% |
| Net margin (%) | 12.3 | — | 18.8 |
Consolidated
- Filed with BSE
- 30 Jan 2019, 18:33 IST
- Board meeting
- 30 Jan 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Jan 2019, 18:33 IST
- Board meeting
- 30 Jan 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Audited
- Source
- XBRL filing on BSE